Company AI Risk Explorer
Loading the data…
Welcome to the Company AI Risk Explorer

This tool maps what large global companies say in public about AI risk. We reviewed public documents from roughly 200 of the world's largest companies. We coded every risk they acknowledge against the AI Risk Repository taxonomy.

Filter by company, sector, AI role, or risk. Compare what companies acknowledge against expert ratings of severity, sector vulnerability, and role responsibility.

← Back to the overview Company AI Risk Explorer

Companies × risks

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals deploys AI through organisation-wide exploration of GenAI/LLMs with global guidelines and external AI partnerships for R&D and analytics. It also trains domain-specific models, including computer vision on MRI for disease differentiation and ML to optimise RNAi therapeutics.

We reviewed 2 public documents from Alnylam Pharmaceuticals and found it acknowledges 2 of 24 AI risks: discrimination and transparency & interpretability.

Sector: Agriculture, Mining, Construction and Manufacturing; Chemicals & pharmaceutical manufacturing

Roles: AI deployer

AI risks Alnylam Pharmaceuticals acknowledges

  • Discrimination: “ensure that they do not cause harm, or result in discrimination or injustice... We strive to avoid unfair bias... We make sure that the algorithms we use are not biased (e.g. using an inadequate data set)” (Responsible Use of Artificial Intelligence)
  • Transparency & interpretability: “mitigate the risks and challenges associated with AI, such as ... transparency, explainability” (Responsible Use of Artificial Intelligence)

Documents we reviewed